ESMO 2022 | Defining and classifying oligometastatic prostate cancer

Nicholas James, MBBS, PhD, FRCP, FRCR, The Royal Marsden NHS Foundation Trust, London, UK, discusses the variations of oligometastatic prostate cancer and their management. Oligometastatic prostate cancer can be divided into synchronous disease with an untreated primary tumor or prostate cancer that has been previously treated with surgery and relapsed. Patients with the latter tend to have more favorable outcomes, with data from the Phase III STAMPEDE trial (NCT00268476) demonstrating that treating the primary tumor is beneficial. However, further research is required to assess if treating the metastases with stereotactic radiotherapy will provide additional benefit. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.